Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. [electronic resource]
Producer: 20160202Description: 1648-66 p. digitalISSN:- 1524-4539
- Adipocytes -- metabolism
- Animals
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Brain -- metabolism
- Cardiovascular Diseases -- enzymology
- Cholesterol, LDL -- metabolism
- Clinical Trials as Topic
- Genetic Predisposition to Disease
- Humans
- Hyperlipoproteinemias -- genetics
- Incidence
- Intestinal Mucosa -- metabolism
- Liver -- metabolism
- Mice
- Molecular Targeted Therapy
- Mutation
- Oligonucleotides, Antisense -- therapeutic use
- Peptide Fragments -- therapeutic use
- Proprotein Convertase 9
- Proprotein Convertases -- antagonists & inhibitors
- Protein Structure, Tertiary
- RNA Interference
- RNA, Small Interfering -- therapeutic use
- Receptors, LDL -- metabolism
- Serine Endopeptidases -- chemistry
- Structure-Activity Relationship
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.